Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Issa Sabi

Showing results (41-50 of 41) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 41 results.
The Lancet. Infectious Diseases|March 8, 2025
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trialÁlvaro H Borges, Marisa Russell, Dereck Tait, et al.
Pageof 5

Showing results (41-50 of 41) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 41 results.
The Lancet. Infectious Diseases|March 8, 2025
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trialÁlvaro H Borges, Marisa Russell, Dereck Tait, et al.
Pageof 5